Skip to main content
Caplight Logo









Athos Therapeutics

Athos Therapeutics

Private
Los Angeles, CaliforniaHealthcare & Life Scienceshttps://athostx.com/

Last Round

Seed Round

May 15, 2026

Total Funding Raised

$54.25M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Athos Therapeutics is a biotechnology company that develops an artificial intelligence technology platform and therapeutics aimed at patients with inflammatory bowel and autoimmune diseases, utilizing machine learning to discover and develop personalized drug and gene targets.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, ML Platforms

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Infrastructure

Keywords

drug discoverysmall molecule therapeuticsAI drug discoverybiotechmulti-omicsbiomarker identificationAI-driven discoveryprecision medicineclinical-stage biotechagentic AIin silico drug discoveryno-code AIomics analysisAI-native biotechdrug discovery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Athos Therapeutics Comparables

Compare Athos Therapeutics with similar companies based on industry and business-model similarity.

Athos Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Auransa
82%
Omic.ai
79%
Genesis Molecular AI
79%

Athos Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundMay 15, 2026
Series BFeb 16, 2024
Series ANov 15, 2021
SeedMar 1, 2020

Key People

Founding team and executive leadership

DIMITRIOS ILIOPOULOS

Co-founder, President & CEO

Founding Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Raised $10.3M in a seed funding round.

  • Mar 10, 2026

    CEO to speak at The Montgomery Summit on March 10-11, 2026.

Athos Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Athos Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Athos Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLos Angeles, California
Employee Range41
Year Founded2019
Last FundingMay 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?